Patents by Inventor Rochelle Mineau

Rochelle Mineau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Follistatin in treating duchenne muscular dystrophy
    Patent number: 10723772
    Abstract: The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of a recombinant follistatin protein such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: July 28, 2020
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventor: Rochelle Mineau
  • Follistatin in Treating Duchenne Muscular Dystrophy
    Publication number: 20180305421
    Abstract: The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of a recombinant follistatin protein such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.
    Type: Application
    Filed: April 12, 2018
    Publication date: October 25, 2018
    Inventor: Rochelle Mineau
  • Follistatin in treating duchenne muscular dystrophy
    Patent number: 9957309
    Abstract: The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of a recombinant follistatin protein such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: May 1, 2018
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventor: Rochelle Mineau
  • FOLLISTATIN IN TREATING DUCHENNE MUSCULAR DYSTROPHY
    Publication number: 20160083440
    Abstract: The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of a recombinant follistatin protein such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.
    Type: Application
    Filed: January 24, 2014
    Publication date: March 24, 2016
    Applicant: Shire Human Genetic Therapies, Inc.
    Inventor: Rochelle Mineau
  • Hybrid matrix implants and explants
    Patent number: 6582391
    Abstract: An implantable device having a body of matrix material made up of insoluble collagen fibrils, and disposed therewithin (a) a plurality of vertebrate cells; and (b) a plurality of microspheres each of which consists primarily of one or more of the following materials: collagen, polystyrene, dextran, polyacrylamide, cellulose, calcium alginate, latex, polysulfone, or glass.
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: June 24, 2003
    Assignee: Transkaryotic Therapies, Inc.
    Inventor: Rochelle Mineau-Hanschke
  • Hybrid matrix implants and explants
    Publication number: 20030091545
    Abstract: A composition having a body of matrix material made up of insoluble collagen fibrils, and disposed therewithin
    Type: Application
    Filed: May 31, 2002
    Publication date: May 15, 2003
    Applicant: Transkaryotic Therapies, Inc., Delaware Corporation
    Inventor: Rochelle Mineau-Hanschke
  • Hybrid matrix implants and explants
    Publication number: 20030077260
    Abstract: An implantable device having a body of matrix material made up of insoluble collagen fibrils, and disposed therewithin
    Type: Application
    Filed: July 2, 2002
    Publication date: April 24, 2003
    Applicant: Transkaryotic Therapies, Inc.
    Inventor: Rochelle Mineau-Hanschke
  • Hybrid matrix implants and explants
    Patent number: 6472181
    Abstract: An implantable device having a body of matrix material made up of insoluble collagen fibrils, and disposed therewithin (a) a plurality of vertebrate cells; and (b) a plurality of microspheres each of which consists primarily of one or more of the following materials: collagen, polystyrene, dextran, polyacrylamide, cellulose, calcium alginate, latex, polysulfone, or glass.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: October 29, 2002
    Assignee: Transkaryotic Therapies, Inc.
    Inventor: Rochelle Mineau-Hanschke
  • Hybrid matrix implants and explants
    Patent number: 6419920
    Abstract: A composition having a body of matrix material made up of insoluble collagen fibrils, and disposed therewithin (a) a plurality of vertebrate cells; (b) a plurality of microspheres; and (c) an agent such as a factor that promotes vascularization, a cytokine, a growth factor, or ascorbic acid.
    Type: Grant
    Filed: October 5, 1999
    Date of Patent: July 16, 2002
    Assignee: Trans Karyotic Therapies, Inc.
    Inventor: Rochelle Mineau-Hanschke
  • Hybrid matrix implants and explants
    Patent number: 5965125
    Abstract: An implantable device having a body of matrix material made up of insoluble collagen fibrils, and disposed therewithin(a) a plurality of vertebrate cells; and(b) a plurality of microspheres each of which consists primarily of one or more of the following materials: collagen, polystyrene, dextran, polyacrylamide, cellulose, calcium alginate, latex, polysulfone, or glass.
    Type: Grant
    Filed: October 25, 1995
    Date of Patent: October 12, 1999
    Assignee: Transkaryotic Therapies, Inc.
    Inventor: Rochelle Mineau-Hanschke